Mangrove Partners IM LLC Acquires New Position in Establishment Labs Holdings Inc. $ESTA

Mangrove Partners IM LLC acquired a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,834 shares of the company’s stock, valued at approximately $1,154,000. Mangrove Partners IM LLC owned about 0.05% of Establishment Labs as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quarry LP bought a new stake in Establishment Labs in the third quarter valued at about $34,000. Kestra Advisory Services LLC bought a new stake in Establishment Labs in the fourth quarter valued at about $47,000. Osaic Holdings Inc. increased its holdings in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the last quarter. Truist Financial Corp bought a new position in shares of Establishment Labs during the fourth quarter valued at approximately $200,000. Finally, PharVision Advisers LLC bought a new position in shares of Establishment Labs during the third quarter valued at approximately $203,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Stock Down 1.9%

NASDAQ:ESTA opened at $82.57 on Wednesday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The stock has a 50 day moving average of $69.81 and a 200-day moving average of $69.38. The firm has a market capitalization of $2.43 billion, a PE ratio of -55.42 and a beta of 1.11. Establishment Labs Holdings Inc. has a 52 week low of $33.35 and a 52 week high of $86.00.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s quarterly revenue was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. Analysts predict that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Analysts Set New Price Targets

ESTA has been the subject of several recent research reports. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. BTIG Research upped their target price on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Canaccord Genuity Group upped their target price on Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.14.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 330,000 shares of company stock worth $22,854,538 in the last three months. Insiders own 9.99% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.